Morgan Stanley analyst Drew Ranieri maintained a Sell rating on Avanos Medical (AVNS – Research Report) today and set a price target of $28.00. The company’s shares opened today at $29.03.
Ranieri covers the Healthcare sector, focusing on stocks such as Becton Dickinson, Haemonetics, and Intuitive Surgical. According to TipRanks, Ranieri has an average return of -7.8% and a 40.74% success rate on recommended stocks.
Avanos Medical has an analyst consensus of Moderate Sell, with a price target consensus of $26.50.
See the top stocks recommended by analysts >>
The company has a one-year high of $35.91 and a one-year low of $19.32. Currently, Avanos Medical has an average volume of 209.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avanos Medical, Inc. is a medical technology company, which focuses on delivering clinically medical device solutions to improve patients’ quality of life. Its portfolio of innovative product offerings focused on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.
Read More on AVNS:
